Headlines Covid-19 Specialties Trending Feeds Videos

Extended follow-up of patients enrolled in the ongoing phase 2 DREAMM-2 study confirms sustained clinical activity without new safety signals in patients with relapsed...

Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments....

Background The evolving nature of multiple myeloma (MM) therapies, including the introduction of novel oral agents, has produced a shift in the delivery of...

Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical...

  • A twist in melflufen story- worse OS in OCEAN study prompts halt of melflufen studies! -In multiply relapsed disease, OS should be endpoint. -mechanism of action is overrated. - this halts the grossly unethical LIGHTHOUSE study which is a win https://t.co/7OkaoxnZPG #mmsm - view on twitter

National Cancer Institute, Rockville, MD,...

In the article that accompanies this editorial, Richardson et al1 present long-term follow-up on the phase III TOURMALINE-MM1 trial and report no improvement in...

The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons...

In this issue of Blood, Facon et al report the results of the large randomized Tourmaline 2 trial including 705 transplantation-ineligible patients with newly...

Surrogate endpoints are being used more frequently in randomized controlled trials, even though they do not consistently corelate with patient outcomes. We systemically evaluated...

Clinical trials may be inconsistent in their enrollment and reporting of patients with multiple myeloma (MM) who have renal insufficiency (RI). We performed a...